Workshop on growth factors.
The 'Workshop on Growth Factors' which took place at the Lugano Lymphoma Conference on June 8, 1990, included a presentation by Michael Sporn on the concept that loss of inhibitory control mechanisms may be important in the development and growth of human cancer. Examples illustrating this were taken from current experimental biology research into transforming growth factor beta (TGF-beta) interactions. Brian Durie presented recent data on the biology of interleukin-6 (IL-6) and its putative role in plasma cell diseases. These studies have culminated in the first clinical study of the role of an antibody to a growth factor as therapy for a human cancer (anti-IL-6 antibody as therapy for patients with myeloma). Derek Crowther presented data concerning the current clinical role of the haematopoietic growth factors in patients undergoing chemotherapy for cancer. Recent clinical research has established the role of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in improving the safety of high-dose or accelerated chemotherapy, and their use is associated with enhanced neutrophil recovery following ablative therapy and bone marrow rescue. This session was followed by the presentation of three papers concerning the use of G-CSF and GM-CSF in association with chemotherapy for patients with malignant lymphoma.
Crowther
D
D
Christie Hospital, Manchester, UK.
Sporn
M B
MB
Roberts
A B
AB
Durie
B G
BG
D000818:Animals; D006133:Growth Substances / Q000502:physiology*; D016298:Hematopoietic Cell Growth Factors / Q000502:physiology; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D008232:Lymphoproliferative Disorders / Q000503:physiopathology*; D016212:Transforming Growth Factor beta / Q000502:physiology
D006133:Growth Substances; D016298:Hematopoietic Cell Growth Factors; D015850:Interleukin-6; D016212:Transforming Growth Factor beta